40 related articles for article (PubMed ID: 25881691)
1. Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
Demine S; Schulte ML; Territo PR; Eizirik DL
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019671
[TBL] [Abstract][Full Text] [Related]
2. Imaging of beta-cell mass and function.
Ichise M; Harris PE
J Nucl Med; 2010 Jul; 51(7):1001-4. PubMed ID: 20554742
[TBL] [Abstract][Full Text] [Related]
3. Clinical and scientific value in the pursuit of quantification of beta cells in the pancreas by PET imaging.
Cline GW; McCarthy TJ; Carson RE; Calle RA
Diabetologia; 2018 Dec; 61(12):2671-2673. PubMed ID: 30136144
[No Abstract] [Full Text] [Related]
4. Characterization and comparison of insulinoma tumor model and pancreatic damage caused by the tumor, and identification of possible markers.
Karatug Kacar A; Bulutay P; Aylar D; Celikten M; Bolkent S
Mol Biol Rep; 2024 Jan; 51(1):109. PubMed ID: 38227104
[TBL] [Abstract][Full Text] [Related]
5. Combined Optical Coherence and Fluorescence Microscopy to assess dynamics and specificity of pancreatic beta-cell tracers.
Berclaz C; Pache C; Bouwens A; Szlag D; Lopez A; Joosten L; Ekim S; Brom M; Gotthardt M; Grapin-Botton A; Lasser T
Sci Rep; 2015 May; 5():10385. PubMed ID: 25988507
[TBL] [Abstract][Full Text] [Related]
6. Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells.
Burtea C; Laurent S; Crombez D; Delcambre S; Sermeus C; Millard I; Rorive S; Flamez D; Beckers MC; Salmon I; Vander Elst L; Eizirik DL; Muller RN
Contrast Media Mol Imaging; 2015; 10(5):398-412. PubMed ID: 25930968
[TBL] [Abstract][Full Text] [Related]
7. Effect of HIV-1 Protease Inhibitor on IL-18 and IL-1
Lou H; Guo L
Dis Markers; 2022; 2022():1868749. PubMed ID: 35601743
[TBL] [Abstract][Full Text] [Related]
8. Lessons from 11C-dihydrotetrabenazine imaging in a xenograft mouse model of rat insulinoma: is PET imaging of pancreatic beta cell mass feasible?
Collantes M; Barajas M; Quincoces G; Ramos-Membrive R; Martí-Climent JM; Ecay M; Rodríguez S; Escalada J; Peñuelas I
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):447-455. PubMed ID: 25881691
[TBL] [Abstract][Full Text] [Related]
9. A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.
Huang ZR; Tsai CL; Huang YY; Shiue CY; Tzen KY; Yen RF; Hsin LW
PLoS One; 2016; 11(9):e0161295. PubMed ID: 27612194
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.
Souza F; Simpson N; Raffo A; Saxena C; Maffei A; Hardy M; Kilbourn M; Goland R; Leibel R; Mann JJ; Van Heertum R; Harris PE
J Clin Invest; 2006 Jun; 116(6):1506-13. PubMed ID: 16710474
[TBL] [Abstract][Full Text] [Related]
11. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
12. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
